文献速递血栓与止血

瑞舒伐他汀增加既往静脉血栓栓塞症患者血浆纤溶潜能:一项随机临床试验

Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.
PubMed 文献 · Br J Haematol · 2020-04-16

该研究为START试验的事后分析,纳入既往确诊静脉血栓栓塞症且已停抗凝治疗者,比较瑞舒伐他汀组(n=126)与无他汀组(n=121)4周后纤溶指标变化。结论提示瑞舒伐他汀可提高纤溶潜能。

要点

  • 瑞舒伐他汀治疗4周可缩短凝块溶解时间,提高纤溶潜能。
  • 瑞舒伐他汀组纤溶酶抑制剂和TAFI活性降低,PAI-1无变化。

核心结论

  • 在既往静脉血栓栓塞症患者中,瑞舒伐他汀使用较无他汀使用提高血浆纤溶潜能。
  • 研究结果支持进一步探索他汀在静脉血栓栓塞症二级预防中的可能作用。

研究设计与样本

  • STArins Reduce Thrombophilia(START)研究(NCT01613794)的事后分析。
  • 既往确诊静脉血栓栓塞症且已结束抗凝治疗的参与者,随机接受瑞舒伐他汀或无治疗4周。
  • 瑞舒伐他汀组n=126,无他汀组n=121;比较基线与4周后纤溶指标。

主要发现

  • 无他汀组研究结束时血浆纤溶潜能及各项纤溶参数较基线无变化。

临床怎么用

  • 对于既往静脉血栓栓塞症且已停抗凝的患者,瑞舒伐他汀可能改善纤溶平衡。
  • 他汀在静脉血栓栓塞症二级预防中的作用尚需进一步研究,暂不能据此改变临床实践。

局限性

  • 本研究为START试验的事后分析。
  • 原文摘要未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a study to assess the effect of rosuvastatin use on fibrinolysis in patients with previous venous thromboembolism (VTE). This was a post hoc analysis within the STAtins Reduce Thrombophilia (START) study (NCT01613794). Plasma fibrinolytic potential, fibrinogen, plasmin inhibitor, plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) were measured before and after four weeks of rosuvastatin or no treatment in participants with prior confirmed VTE, after ending anticoagulant therapy. In the non-rosuvastatin group (n = 121), plasma fibrinolytic potential and individual fibrinolysis parameters did not change at the end of the study versus the baseline, whereas in the rosuvastatin group (n = 126), plasma fibrinolytic potential increased: the mean clot lysis time decreased by 8·75 min (95% CI -13·8 to -3·72), and plasmin inhibitor levels and TAFI activity were lower at the end of the study (-0·05 U/ml; 95% CI -0·07 to -0·02 and -4·77%; 95% CI -6·81 to -2·73, respectively). PAI-1 levels did not change and fibrinogen levels were 0·17 g/l (95% CI 0·04-0·29) higher. In participants with prior VTE, rosuvastatin use led to an increased fibrinolytic potential compared with non-statin use. Our findings support the need for further studies on the possible role for statins in the secondary prevention of VTE.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Schol-Gelok S, de Maat MPM, Biedermann JS, et al. Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. Br J Haematol. 2020. PMID: 32301122. doi:10.1111/bjh.16648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。